StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) stock

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.23−0.25 (-3.86%)

Close on Nov 17, 2026Market cap $668.01MP/E –Yield –

Solid Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Solid Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$186.84M. For fiscal 2025 it was -$156.29M. The highest annual figure on record is -$20.12M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$156.29M–
FY2024Dec 31, 2024-$100.01M–
FY2023Dec 31, 2023-$94.18M–
FY2022Dec 31, 2022-$97.98M–
FY2021Dec 31, 2021-$77.76M–
FY2020Dec 31, 2020-$56.60M–
FY2019Dec 31, 2019-$92.71M–
FY2018Dec 31, 2018-$70.20M–
FY2017Dec 31, 2017-$43.22M–
FY2016Dec 31, 2016-$20.12M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$52.59M–
Q1 FY2026Mar 31, 2026-$47.23M–
Q4 FY2025Dec 31, 2025-$53.56M–
Q3 FY2025Sep 30, 2025-$33.47M–
Q2 FY2025Jun 30, 2025-$37.41M–
Q1 FY2025Mar 31, 2025-$31.85M–
Q4 FY2024Dec 31, 2024-$29.65M–
Q3 FY2024Sep 30, 2024-$23.71M–
Q2 FY2024Jun 30, 2024-$21.47M–
Q1 FY2024Mar 31, 2024-$25.19M–
Q4 FY2023Dec 31, 2023-$20.82M–
Q3 FY2023Sep 30, 2023-$17.90M–
Q2 FY2023Jun 30, 2023-$27.47M–
Q1 FY2023Mar 31, 2023-$28.00M–
Q4 FY2022Dec 31, 2022-$34.48M–
Q3 FY2022Sep 30, 2022-$20.43M–
Q2 FY2022Jun 30, 2022-$15.88M–
Q1 FY2022Mar 31, 2022-$27.19M–
Q4 FY2021Dec 31, 2021-$20.87M-1697.1%
Q3 FY2021Sep 30, 2021-$18.42M–
Q2 FY2021Jun 30, 2021-$17.10M–
Q1 FY2021Mar 31, 2021-$21.37M–
Q4 FY2020Dec 31, 2020$1.31M–
Q3 FY2020Sep 30, 2020-$15.56M–
Q2 FY2020Jun 30, 2020-$13.07M–
Q1 FY2020Mar 31, 2020-$29.27M–
Q4 FY2019Dec 31, 2019-$21.25M–
Q3 FY2019Sep 30, 2019-$19.24M–
Q2 FY2019Jun 30, 2019-$26.30M–
Q1 FY2019Mar 31, 2019-$25.93M–
Q4 FY2018Dec 31, 2018-$21.40M–
Q3 FY2018Sep 30, 2018-$15.29M–
Q2 FY2018Jun 30, 2018-$16.33M–
Q1 FY2018Mar 31, 2018-$17.17M–
Q4 FY2017Dec 31, 2017-$13.98M–
Q3 FY2017Sep 30, 2017-$9.44M–
Q2 FY2017Jun 30, 2017-$9.61M–
Q1 FY2017Mar 31, 2017-$10.20M–

More Solid Biosciences figures

See a number that looks wrong?